A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia

被引：0
|
作者：
Absalon, Michael J. [1 ]
Breese, Erin H. [1 ]
Lee, Lynn [1 ]
O'Brien, Maureen M. [1 ]
Phillips, Christine L. [1 ]
Burns, Karen [1 ]
Mizukawa, Benjamin [1 ]
An, Qi [2 ]
Mangino, Jennifer [1 ]
Kaplan, Joel [3 ]
Norris, Robin [1 ]
Perentesis, John Peter [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA
[2] Jazz Pharmaceut, Palo Alto, CA USA
[3] Levine Childrens Hosp, Carolinas Med Ctr, Charlotte, NC USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-119618
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
336
引用
收藏
页数：2
相关论文
共 50 条
  • [41] A PILOT STUDY OF MITOXANTRONE IN COMBINATION WITH CLOFARABINE (MITCL) IN CHILDREN, ADOLESCENTS AND YOUNG ADULTS (CAYA) WITH REFRACTORY/RELAPSED ACUTE LEUKEMIA
    Hochberg, Jessica
    Oesterheld, Javier
    Militano, Olga
    Roy, Sumith
    Harrison, Lauren
    Cairo, Mitchell
    PEDIATRIC BLOOD & CANCER, 2015, 62 : 96 - 96
  • [42] Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia.
    Hochberg, Jessica
    Oesterheld, Javier E.
    Militano, Olga
    Klejmont, Liana
    Harrison, Lauren
    Nickerson, Berkley
    Cairo, Mitchell S.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] A Phase 1b/2 Trial of Liposomal Cytarabine and Daunorubicin (CPX-351) in Intermediate to High-Risk Acute Myeloid Leukemia for Patients Who Have Failed an Initial Cycle of Induction Chemotherapy
    Pontious, Corbin
    Garzon, Ramiro
    Blachly, James S.
    Blaser, Bradley Wayne
    Choe, Hannah
    Grieselhuber, Nicole R.
    Long, Meixiao
    Vasu, Sumithira
    Wall, Sarah A.
    Larkin, Karilyn T.
    Eisfeld, Ann-Kathrin
    Koenig, Kristin L.
    Sahasrabudhe, Kieran D.
    Sanchez-Petitto, Gabriela
    Saad, Ayman
    Bhatnagar, Bhavana
    Lyberger, Justin
    Borate, Uma M.
    Mims, Alice
    Jonas, Brian A.
    Behbehani, Gregory K.
    BLOOD, 2023, 142
  • [44] A phase I/II study of SDZ PSC 833 (PSC) in combination with daunorubicin (D) and cytarabine in refractory acute myelogenous leukemia (AML).
    Liliemark, J
    Bjorkholm, M
    Uden, AM
    Hast, R
    Paul, C
    Simonsson, B
    Tidefelt, U
    Juliusson, G
    Hedenus, M
    Evensen, S
    Tangen, JM
    Sjo, M
    Nesthus, I
    Hestdal, K
    BLOOD, 1996, 88 (10) : 854 - 854
  • [45] Phase I study of vinblastine in combination with nilotinib in children, adolescents, and young adults with refractory or recurrent low-grade glioma
    Vairy, Stephanie
    Le Teuff, Gwenael
    Bautista, Francisco
    De Carli, Emilie
    Bertozzi, Anne-Isabelle
    Pagnier, Anne
    Fouyssac, Fanny
    Nysom, Karsten
    Aerts, Isabelle
    Leblondt, Pierre
    Millot, Frederic
    Berger, Claire
    Canale, Sandra
    Paci, Angelo
    Poinsignon, Vianney
    Chevance, Aurelie
    Ezzalfani, Monia
    Vidaud, Dominique
    Di Giannatale, Angela
    Hladun-Alvaro, Raquel
    Petit, Francois M.
    Vassal, Gilles
    Geoerger, Birgit
    Le Deleyt, Marie-Cecile
    Grill, Jacques
    NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
  • [46] A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study
    Wierzbowska, Agnieszka
    Pluta, Agnieszka
    Stelmach, Piotr
    Brzozowski, Kamil
    Czemerska, Magdalena
    Sobas, Marta
    Rybka, Justyna
    Wrobel, Tomasz
    Zarzycka, Ewa
    Prejzner, Witold
    Zaucha, Jan M.
    Szczepaniak, Andrzej
    Gil, Lidia
    Giebel, Sebastian
    BLOOD, 2023, 142
  • [47] Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin
    Kolitz, Jonathan
    Strickland, Stephen A.
    Cortes, Jorge E.
    Hogge, Donna
    Lancet, Jeffrey E.
    Goldberg, Stuart
    Ryan, Robert J.
    Chiarella, Michael
    Louie, Arthur C.
    Uy, Geoffrey L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 : S208 - S209
  • [48] A Pilot Phase II Study of the Feasibility and Efficacy of Vincristine Sulfate Liposome Injection in Patients With Relapsed or Refractory Acute Myeloid Leukemia
    Seegars, Mary Beth
    Woods, Ryan
    Ellis, Leslie R.
    Bhave, Rupali Roy
    Howard, Dianna S.
    Manuel, Megan
    Dralle, Sarah
    Lyerly, Susan
    Powell, Bayard L.
    Pardee, Timothy S.
    JOURNAL OF HEMATOLOGY, 2021, 10 (01) : 1 - 7
  • [49] Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Acute Myeloid Leukemia (AML) and PostHypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)
    Rivera, Daniel
    Kadia, Tapan M.
    Montalban-Bravo, Guillermo
    Faderl, Stefan
    Sasaki, Koji
    Short, Nicholas J.
    Daver, Naval
    Di Nardo, Courtney D.
    Masarova, Lucia
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Borthakur, Gautham
    Al Azzawi, Hind
    Konopleva, Marina
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Kantarjian, Hagop
    Ravandi, Farhad
    Alvarado, Yesid
    BLOOD, 2021, 138
  • [50] Phase I study of talazoparib and irinotecan in children and young adults with recurrent/refractory solid tumors.
    Federico, Sara Michele
    Stewart, Elizabeth
    Coleman, Jamie L.
    Bishop, Michael William
    Santana, Victor M.
    Lam, Catherine
    Hawkins, Dana
    Wu, Jianrong
    Mao, Shenghua
    Goshorn, David Ross
    Papp, Alberto S.
    Dyer, Michael A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345